Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE ROS1 GENE REARRANGEMENT
    Ou, Sai-hong I.
    Bang, Y-j
    Camidge, D. R.
    Engelman, J. A.
    Clark, J. W.
    Tye, L.
    Wilner, Keith
    Stephenson, P.
    Chung, D. H.
    Varella-Garcia, M.
    Iafrate, A. J.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S455 - S455
  • [2] Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
    Yang, Guangdie
    Wang, Jie
    Yao, Yinan
    Zhao, Jun
    Yu, Zheyan
    Gao, Qiqi
    Ye, Jiani
    Ma, Wenjiang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures
    Deng, Huiyan
    Liu, Chang
    Zhang, Guoliang
    Wang, Xiaoling
    Liu, Yueping
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (12) : 2103 - 2105
  • [4] Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?
    Han, B.
    Zhang, B.
    Xu, J.
    Zhang, Y.
    Zhang, X.
    Chu, T.
    Wang, S.
    Qiao, R.
    Qian, J.
    Lu, J.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S471 - S471
  • [5] Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
    Dong, Liang
    Xia, Jingwen
    Zhang, Jing
    Zhang, Yuanyuan
    Zhu, Ning
    Zhang, Peng
    Zhang, Youzhi
    Zhang, Xiujuan
    Li, Shengqing
    BMC PULMONARY MEDICINE, 2018, 18
  • [6] Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
    Liang Dong
    Jingwen Xia
    Jing Zhang
    Yuanyuan Zhang
    Ning Zhu
    Peng Zhang
    Youzhi Zhang
    Xiujuan Zhang
    Shengqing Li
    BMC Pulmonary Medicine, 18
  • [7] Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
    Zhao, Zheng
    Song, Zhangjun
    Wang, Xuwei
    Sun, Haifeng
    Yang, Xiaomin
    Yuan, Yong
    Yu, Pan
    ONCOTARGETS AND THERAPY, 2017, 10 : 4129 - 4133
  • [8] Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib
    Xu, Long
    Chen, Xiaoxia
    Huo, Hong
    Liu, Yongye
    Yang, Xiaodan
    Gu, Dejian
    Yuan, Mingming
    Zhang, Min
    Chen, Rongrong
    Wang, Jiayin
    Zheng, Zhendong
    FRONTIERS IN MEDICINE, 2021, 8
  • [9] Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report
    Wang, W.
    Xu, C.
    Zhu, Y.
    Liao, X.
    Zhuang, W.
    Du, K.
    Chen, R.
    Chen, Y.
    Chen, G.
    Fang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2244 - S2244
  • [10] A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
    Tachi, Hiroaki
    Nishino, Kengo
    Nakaizumi, Taisuke
    Kuramoto, Kenya
    Shimizu, Kei
    Yamamoto, Yusuke
    Kobayashi, Keisuke
    Ichimura, Hideo
    Sakata, Akiko
    Nawa, Takeshi
    THORACIC CANCER, 2020, 11 (07) : 2063 - 2066
12345